StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for LNSR yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $11.75M | $51.66M | $37.32M | $24.57M |
Operating Income | $2.24M | $-24.58M | $-19.66M | $-12.08M |
Net Income | $36.33M | $-34.28M | $-32.82M | $-1.76M |
EPS (Diluted) | $0.00 | $-2.87 | $-2.75 | $-2.46 |
Total Assets | $66.22M | $71.43M | $70.20M | $70.41M |
Total Liabilities | $41.65M | $83.67M | $82.33M | $79.68M |
Cash & Equivalents | $12.49M | $12.97M | $7.64M | $7.15M |
Free Cash Flow OCF − CapEx | Not available | $-14.91M | $-15.53M | $-12.02M |
Shares Outstanding | 12.10M | 11.99M | 11.94M | 11.93M |
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-20 | $5.79 | $5.88 | +1.55% | 0.1M |
| 05-21 | $5.83 | $5.95 | +2.06% | 0.1M |
| 05-22 | $5.95 | $6.09 | +2.35% | 0.0M |
| 05-26 | $6.10 | $6.05 | -0.82% | 0.0M |
| 05-27 | $6.06 | $6.03 | -0.50% | 0.0M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.